Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2023 May:106:108094.
doi: 10.1016/j.ijscr.2023.108094. Epub 2023 Mar 30.

Multiple ulcers and perforation of small intestine with everolimus use in a patient with rectal neuroendocrine tumor: A case report

Affiliations
Case Reports

Multiple ulcers and perforation of small intestine with everolimus use in a patient with rectal neuroendocrine tumor: A case report

Kentaro Abe et al. Int J Surg Case Rep. 2023 May.

Abstract

Introduction: Everolimus is an orally administered inhibitor of the mammalian target of rapamycin, which is a serine/threonine protein kinase. It is used for the treatment of pancreatic and gastrointestinal neuroendocrine tumors (NETs). Gastrointestinal perforations in patients being treated with everolimus is extremely rare, with only five reported cases.

Case presentation: A 62-year-old woman, who had previously undergone surgery for rectal NET, presented to our hospital with fever and abdominal pain. Abdominal computed tomography revealed perforation of the lower gastrointestinal tract, and we performed emergency surgery. There were multiple ulcers 150 cm distal from the ligament of Treitz to the terminal ileum; an ulcer at the anastomosis of stoma closure, 35 cm from the terminal ileum, was transmural. We subsequently performed a partial intestinal resection.

Clinical discussion: The diagnosis of NETs is increasing worldwide, owing to recent improvements in diagnostic techniques. Although the use of everolimus has increased, gastrointestinal ulcer perforations caused by everolimus treatment have rarely been reported. The mechanism may be due to the inhibition of angiogenesis by mTOR inhibitors, as well as vascular endothelial growth factor inhibitors. In this case, It was considered that everolimus use most likely caused perforation.

Conclusion: It is necessary to recognize that drug-induced gastrointestinal ulcers and perforations may occur with the use of mTOR inhibitors, and careful follow-up should be performed during administration.

Keywords: Everolimus; Multiple ulcers; Perforation.

PubMed Disclaimer

Conflict of interest statement

Conflict of interest statement The authors declare that they have no conflict of interest.

Figures

Fig. 1
Fig. 1
Abdominal computed tomography (CT) revealing free air on the right side of the anastomosis of the ileostomy reversal in the pelvis (arrow).
Fig. 2
Fig. 2
Intraoperative findings showing white and round ulcers on the serosal surface of the 130-cm small intestine section, starting 150 cm anorectal from the Treitz ligament to the end of the ileum (A, arrowhead). The largest ulceration was found at the anastomosis of the ileostomy reversal 35 cm from the Bauhin valve. The intestinal wall at the site appears to thin, and a 4 mm-sized perforation is observed (B, arrowhead). Abscesses are found around the perforation.
Fig. 3
Fig. 3
Macroscopic evaluation of the resected specimen. Approximately 20 small ulcers with well-defined rounded borders are observed contralaterally to the mesentery in a 117-cm section of the resected intestine (A, arrowheads). The largest ulcer, 35 × 15 mm, is located at the anastomosis of the ileostomy closure (A, arrow), and a 4 mm perforation is found (B, arrow).
Fig. 4
Fig. 4
Histopathological findings of the specimen. Multiple steep and deep ulcers were noted, some of which formed transmural necrosis. (A). Nonspecific acute inflammatory findings, such as intense neutrophilic infiltration (B) and edema are seen around the ulcer area. Scale bar = 2.5 mm (A) or 100 μm (B).

Similar articles

References

    1. Baselga J., Campone M., Piccart M., Burris H.A., Rugo H.S., Sahmoud T., et al. Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N. Engl. J. Med. 2012;366(6):520–529. - PMC - PubMed
    1. Okuyama Y., Honda A., Ri T., Nakatugawa Y., Yamada S., Suzuki T. Everolimus induced colitis and ulcers, report of a case. Stomach Intestine. 2020;7(55):946–950.
    1. Paplomata E., Zelnak A., O’Regan R. Everolimus: side effect profile and management of toxicities in breast cancer. Breast Cancer Res. Treat. 2013;140(3):453–462. - PubMed
    1. Agha R.A., Franchi T., Sohrabi C., Mathew G., for the SCARE Group The SCARE 2020 guideline: updating consensus Surgical Case Report (SCARE) guidelines. Int. J. Surg. 2020;84:226–230. - PubMed
    1. Agha R.A., Borrelli M.R., Farwana R., Koshy K., Fowler A., Orgill D.P., SCARE Group The PROCESS 2018 statement: updating consensus Preferred Reporting Of CasE Series in Surgery (PROCESS) guidelines. Int. J. Surg. 2018;60:279–282. - PubMed

Publication types